[European Commission](https://commission.europa.eu/index_en)

April 13, 2027

€8–10 million per project; total call budget €38 million; project duration typically 3–5 years

Supports research into personalised strategies and technologies to reduce adverse drug reactions from multiple medications, aiming to improve patient safety and healthcare outcomes across Europe.

--- ## Description This grant funds research and innovation actions (RIA) focused on developing personalised approaches to reduce the risks associated with adverse drug reactions (ADRs) due to polypharmacy (the administration of three or more medications). The aim is to integrate genetic, biomarker, and clinical data into medication management using advanced technologies such as electronic health records and artificial intelligence. Projects are expected to identify and validate biomarkers, develop targeted therapies, and utilize data analytics to better predict, prevent, and manage ADRs. The call also emphasizes the generation of robust evidence to inform clinical and regulatory guidelines, enhance healthcare provider and patient education, and promote the adoption of safer medication practices across diverse populations. Collaboration with other EU-funded initiatives and sharing of research data with stakeholders, including the European Medicines Agency, is strongly encouraged. --- ## Due Dates - April 13, 2027: Full application submission deadline (17:00:00 Brussels time) --- ## Funding Amount - Indicative budget for this topic: €38,000,000 - Expected EU contribution per project: €8,000,000 to €10,000,000 - Indicative number of grants: 4 - Typical project duration: 3–5 years --- ## Eligibility - Open to legal entities (universities, research institutes, SMEs, large companies, public bodies, etc.) established in EU Member States and Horizon Europe Associated Countries. - US legal entities are eligible for funding. - Legal entities from China are not eligible for this call. - Proposals are expected to include clinical studies; applicants must use the dedicated clinical studies annex. - See [Annex B of the Work Programme General Annexes](https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2026-2027/wp-15-general-annexes_horizon-2026-2027_en.pdf) for full eligibility details. --- ## Application Process - Single-stage application process. - Proposal submission via the [EU Funding & Tenders Portal](https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-01-CARE-02?isExactMatch=true&status=31094501,31094502&order=DESC&pageNumber=3&pageSize=50&sortBy=startDate). - Detailed instructions, templates, and guidance documents are available on the portal. - Proposals must address all aspects listed in the topic scope, including leveraging pharmacogenomics, technology integration, and regulatory/implementation challenges. - Proposals should avoid overlap with existing EU-funded projects and align with ongoing partnerships where possible. - Evaluation criteria and thresholds are described in [Annex D](https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2026-2027/wp-15-general-annexes_horizon-2026-2027_en.pdf). --- ## Additional Information - The participation of start-ups, micro, small and medium-sized enterprises (SMEs) is encouraged. - Projects must ensure robust data sharing with relevant stakeholders and the European Medicines Agency. - Ethical, regulatory, and implementation challenges must be addressed. - Proposals should consider sex differences, population diversity, and cost-effectiveness. - Entities assessed as high-risk suppliers for mobile network communication equipment are not eligible. - For projects using satellite-based Earth observation or related data, use of Copernicus and/or Galileo/EGNOS is required. --- ## External Links - [Call Details & Application Portal](https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-01-CARE-02?isExactMatch=true&status=31094501,31094502&order=DESC&pageNumber=3&pageSize=50&sortBy=startDate) - [Horizon Europe Programme Guide](https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf) - [General Annexes (Eligibility, Evaluation, Legal)](https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2026-2027/wp-15-general-annexes_horizon-2026-2027_en.pdf) - [Online Manual](https://webgate.ec.europa.eu/funding-tenders-opportunities/display/OM/Online+Manual) - [Partner Search Tool](https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search?order=DESC&pageNumber=1&pageSize=50&sortBy=lastModified&isExactMatch=true&type=ORGANISATION,PERSON&frameworkProgramme=43108390) --- ## Contact Information | Resource | Link/Contact | |---------------------------|--------------------------------------------------------------------------------------------------------| | General Enquiries | [European Commission Contact](https://commission.europa.eu/about-european-commission/contact_en) | | Research Enquiry Service | [Research Enquiry Service](https://research-and-innovation.ec.europa.eu/contact-us/research-enquiry-service_en) | | National Contact Points | [List of NCPs](https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/ncp) | | IT Helpdesk | [Portal IT Helpdesk](https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/helpdesks/contact-form) | | Telephone | +32 2 299 11 11 |

Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications - European Commission

Sign in to see full grant listing